Evolocumab
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Evolocumab |
| DrugBank ID | DB09303 |
| Brand Names (EU) | Repatha |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.82% |
Approved Indication (EMA)
Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicat
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | symptomatic form of hemophilia in female carriers | 99.82% | DL |
| 2 | familial apolipoprotein C-II deficiency | 99.50% | DL |
| 3 | thrombocytopenic purpura | 99.42% | DL |
| 4 | factor XI deficiency | 99.29% | DL |
| 5 | hemophilia A with vascular abnormality | 99.22% | DL |
| 6 | disease of catalytic activity | 99.08% | DL |
| 7 | hemorrhagic disease of newborn | 98.89% | DL |
| 8 | ichthyosis, X-linked, without steroid sulfatase deficiency | 98.84% | DL |
| 9 | inherited thrombophilia | 98.82% | DL |
| 10 | disorder of other vitamins and cofactors metabolism and transport | 98.80% | DL |
| 11 | adenosine deaminase deficiency | 98.80% | DL |
| 12 | xanthomatosis (disease) | 98.78% | DL |
| 13 | esophageal varices without bleeding | 98.75% | DL |
| 14 | esophageal varices with bleeding | 98.75% | DL |
| 15 | 46,XY disorder of sexual development due to dihydrotestosterone backdoor pathway biosynthesis defect | 98.73% | DL |
| 16 | 3-hydroxyacyl-CoA dehydrogenase deficiency | 98.70% | DL |
| 17 | cholesterol catabolic process disease | 98.66% | DL |
| 18 | coagulation protein disease | 98.66% | DL |
| 19 | 46,XY disorder of sex development due to a cholesterol synthesis defect | 98.64% | DL |
| 20 | neutral lipid storage disease | 98.56% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.